Opioid-Induced Constipation (OIC) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 44 Published: March 31, 2022 Report Code: GMDGDHC22077IDB

  • Overview
  • Key Players
  • Contents
  • Tables
  • Figures
  • FAQ
  • Listen
    iSpeech

Opioids are effective pain relievers, but often have the side effect of constipation. These medicines affect the gastrointestinal tract in a variety of ways. Opioids increase the amount of time it takes stool to move through the gastric system. They increase non-propulsive contractions in the middle of the small intestine (jejunum) and decrease longitudinal propulsive peristalsis – motions critical to moving food through the intestines. Additionally, opioids reduce digestive secretions and decrease the urge to defecate. Symptoms of Opioid-Induced Constipation (OIC) include feeling and being sick, tiredness and lethargy, appetite loss, and feeling depressed.

The Opioid-Induced Constipation (OIC) Drugs in Development market research report provides an overview of the OIC pipeline landscape. The report provides comprehensive information on the therapeutics under development for Opioid-Induced Constipation (OIC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opioid-Induced Constipation (OIC) and features dormant and discontinued projects.

OIC Pipeline Drugs Market Targets

The targets of the OIC pipeline drugs market are Mu Type Opioid Receptor, 5-Hydroxytryptamine Receptor 4, and Chloride Channel Protein 2.

OIC pipeline drugs market, by targets

OIC pipeline drugs market, by targets

For more target insights, download a free report sample

Mechanisms of Action of OIC Pipeline Drugs Market

The mechanisms of action of the OIC pipeline drugs market are Mu Type Opioid Receptor Antagonist, 5-Hydroxytryptamine Receptor 4 Agonist, and Chloride Channel Protein 2 Activator.

OIC pipeline drugs market, by mechanisms of action

OIC pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

Routes of Administration in OIC Pipeline Drugs Market

The route of administration in the OIC pipeline drugs market is oral.

Molecule Types in OIC Pipeline Drugs Market

The molecule types in the OIC pipeline drugs market are small molecule and biologic.

OIC pipeline drugs market, by molecule types

OIC pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Key OIC Pipeline Drugs Market Companies

Some of the key companies in the OIC pipeline drugs market are BioGaia Pharma AB, Mallinckrodt Plc, PegBio Co Ltd, Shanghai Hanmai Biomedical Technology Co Ltd, Shionogi & Co Ltd, and Yuhan Corp.

OIC pipeline drugs market, by key companies

OIC pipeline drugs market, by key companiesTo know more about key companies, download a free report sample

Market report overview

Targets Mu Type Opioid Receptor, 5-Hydroxytryptamine Receptor 4, and Chloride Channel Protein 2
Mechanisms of Action Mu Type Opioid Receptor Antagonist, 5-Hydroxytryptamine Receptor 4 Agonist, and Chloride Channel Protein 2 Activator
Routes of Administration Oral
Molecule Types Small Molecule and Biologic
Key Companies BioGaia Pharma AB, Mallinckrodt Plc, PegBio Co Ltd, Shanghai Hanmai Biomedical Technology Co Ltd, Shionogi & Co Ltd, and Yuhan Corp

Scope

 This report provides:

  • A snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC) (Toxicology).
  • Reviews of pipeline therapeutics for Opioid-Induced Constipation (OIC) (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key companies involved in Opioid-Induced Constipation (OIC) (Toxicology) therapeutics and enlists all their major and minor projects.
  • Evaluation of Opioid-Induced Constipation (OIC) (Toxicology) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Opioid-Induced Constipation (OIC) (Toxicology).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Opioid-Induced Constipation (OIC) (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Players

BioGaia Pharma AB

Mallinckrodt Plc

PegBio Co Ltd

Shanghai Hanmai Biomedical Technology Co Ltd

Shionogi & Co Ltd

Yuhan Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Opioid-Induced Constipation (OIC) – Overview

Opioid-Induced Constipation (OIC) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Opioid-Induced Constipation (OIC) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Opioid-Induced Constipation (OIC) – Companies Involved in Therapeutics Development

BioGaia Pharma AB

Mallinckrodt Plc

PegBio Co Ltd

Shanghai Hanmai Biomedical Technology Co Ltd

Shionogi & Co Ltd

Yuhan Corp

Opioid-Induced Constipation (OIC) – Drug Profiles

BGP-345A – Drug Profile

Product Description

Mechanism Of Action

History of Events

lubiprostone – Drug Profile

Product Description

Mechanism Of Action

History of Events

M-02 – Drug Profile

Product Description

Mechanism Of Action

naldemedine tosylate – Drug Profile

Product Description

Mechanism Of Action

History of Events

PB-1902 – Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC – Drug Profile

Product Description

Mechanism Of Action

YH-12852 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Opioid-Induced Constipation (OIC) – Dormant Projects

Opioid-Induced Constipation (OIC) – Discontinued Products

Opioid-Induced Constipation (OIC) – Product Development Milestones

Featured News & Press Releases

Jan 26, 2022: BioGaia Pharma announces first patient enrolled in phase II clinical study evaluating BGP345A for the treatment of opioid induced constipation (OIC-1)

May 15, 2015: Sucampo Announces Clinical Data on Lubiprostone to be Presented at Digestive Disease Week

Dec 30, 2014: Sucampo Announces Acceptance of New Drug Submission for AMITIZA (lubiprostone) by Health Canada

Oct 13, 2014: Clinical Data for AMITIZA Lubiprostone to be Presented at the American College of Gastroenterology 2014 Annual Scientific Meeting

Sep 29, 2014: Sucampo and Takeda Launch Direct-to-Consumer Advertising Campaign for AMITIZA (lubiprostone) for Chronic Idiopathic Constipation

Jul 23, 2014: Sucampo Announces Publication of NICE Recommendation for AMITIZA (Lubiprostone)

Jul 07, 2014: Swissmedic Approves AMITIZA (Lubiprostone) for the Treatment of Opioid-Induced Constipation

Jun 17, 2014: AMITIZA (Lubiprostone) Receives NICE Recommendation

Jun 12, 2014: Sucampo Issues Statement Regarding Anesthetic and Analgesic Drug Products Advisory Committee Meeting’s Vote

May 06, 2014: Sucampo Announces New Data on AMITIZA and Opioid-Induced Constipation Published Online in Pain Medicine Journal

May 01, 2014: Sucampo Announces Clinical Data on Lubiprostone to be Presented at Two Upcoming Scientific Conferences

Apr 25, 2014: Sucampo Pharma To Present Preclinical Data For Lubiprostone at Experimental Biology Conference 2014

Mar 12, 2014: Sucampo Receives Notice that Second Indication for AMITIZA for Opioid-Induced Constipation Is Not Approved by Medicines and Healthcare Products Regulatory Agency in U.K.

Oct 11, 2013: Sucampo Announces Presentation of Results on AMITIZA in Opioid-Induced Constipation at Two Upcoming Scientific Conferences

Oct 08, 2013: Clinical Data Show That Lubiprostone is Efficacious and Well Tolerated in Children and Adolescents With Functional Constipation

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Opioid-Induced Constipation (OIC), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Opioid-Induced Constipation (OIC) – Pipeline by BioGaia Pharma AB, 2022

Opioid-Induced Constipation (OIC) – Pipeline by Mallinckrodt Plc, 2022

Opioid-Induced Constipation (OIC) – Pipeline by PegBio Co Ltd, 2022

Opioid-Induced Constipation (OIC) – Pipeline by Shanghai Hanmai Biomedical Technology Co Ltd, 2022

Opioid-Induced Constipation (OIC) – Pipeline by Shionogi & Co Ltd, 2022

Opioid-Induced Constipation (OIC) – Pipeline by Yuhan Corp, 2022

Opioid-Induced Constipation (OIC) – Dormant Projects, 2022

Opioid-Induced Constipation (OIC) – Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development for Opioid-Induced Constipation (OIC), 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

The targets of the OIC pipeline drugs market are Mu Type Opioid Receptor, 5-Hydroxytryptamine Receptor 4, and Chloride Channel Protein 2.

The mechanisms of action of the OIC pipeline drugs market are Mu Type Opioid Receptor Antagonist, 5-Hydroxytryptamine Receptor 4 Agonist, and Chloride Channel Protein 2 Activator.

The route of administration in the OIC pipeline drugs market is oral.

The molecule types in the OIC pipeline drugs market are small molecule and biologic.

Some of the key companies in the OIC pipeline drugs market are BioGaia Pharma AB, Mallinckrodt Plc, PegBio Co Ltd, Shanghai Hanmai Biomedical Technology Co Ltd, Shionogi & Co Ltd, and Yuhan Corp.

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.